key: cord-0696109-625p8lpm
authors: Kaku, Yu; Kuwata, Takeo; Zahid, Hasan Md; Hashiguchi, Takao; Noda, Takeshi; Kuramoto, Noriko; Biswas, Shashwata; Matsumoto, Kaho; Shimizu, Mikiko; Kawanami, Yoko; Shimura, Kazuya; Onishi, Chiho; Muramoto, Yukiko; Suzuki, Tateki; Sasaki, Jiei; Nagasaki, Yoji; Minami, Rumi; Motozono, Chihiro; Toyoda, Mako; Takahashi, Hiroshi; Kishi, Hiroto; Fujii, Kazuhiko; Tatsuke, Tsuneyuki; Ikeda, Terumasa; Yosuke, Maeda; Ueno, Takamasa; Koyanagi, Yoshio; Iwagoe, Hajime; Matsushita, Shuzo
title: Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19
date: 2021-06-25
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109385
sha: 32097bcd8746f3a9e3d58c6fbd26a95fba9351bb
doc_id: 696109
cord_uid: 625p8lpm

Administration of plasma from convalescent patients or neutralizing monoclonal antibodies (mAbs) is potent therapeutic option for COVID-19 caused by SARS-CoV-2 infection. However, SARS-CoV-2 variants with mutations in the spike protein have emerged in many countries. To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants, we isolate anti-Spike mAbs from two convalescent patients with COVID-19 infected with prototypic SARS-CoV-2 by single cell sorting of IgG+ memory B cells. Anti-Spike antibody induction is robust in these patients and five mAbs have potent neutralizing activities. The efficacy of most neutralizing mAbs and convalescent plasma samples is maintained against B.1.1.7 and mink cluster 5 variants but is significantly decreased against variants B.1.351 from South Africa and P.1 from Brazil. However, mAbs with a high affinity to the receptor-binding domain remain effective against these neutralization-resistant variants. Rapid spread of these variants significantly impacts antibody-based therapies and vaccine strategies against SARS-CoV-2.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus 67 disease 2019 , which emerged in late 2019 and became a global pandemic 68 (Wu et al., 2020a; Zhou et al., 2020; Zhu et al., 2020) . A potent option to treat patients 69 with COVID-19 is the administration of plasma from patients who have recovered from 70 COVID-19 (Duan et al., 2020; Li et al., 2020; Liu et al., 2020b) . Neutralization of 71 viruses by antibodies is considered the main mechanism to control COVID-19 by 72 convalescent plasma. Currently, hundreds of monoclonal antibodies (mAbs) against 73 SARS-CoV-2 have been isolated from convalescent patients with COVID-19 (Barnes et 74 al., 2020; Brouwer et al., 2020; Cao et al., 2020; Kim et al., 2021; Kreye et al., 2020; 75 Liu et al., 2020a) and potent neutralizing mAbs, which mostly target the 76 receptor-binding domain (RBD) of the SARS-CoV-2 Spike (S) protein, have been 77 developed for clinical use (Schäfer et al., 2020; Weinreich et al., 2020) . (Leung et al., 2021; Tegally et al., 2021) . P.1, In 83 Brazil, a variant with unique mutations has emerged in Brazil (Fujino et al., 2021;  84 Maggi et al., 2021) . It is important to clarify whether neutralizing antibodies from 85 convalescent patients infected with the prototypic virus, are effective against emerging 86 SARS-CoV-2 variants for therapy using plasma or antibodies from convalescent 87 patients. Therefore, we examined the sensitivity of neutralizing mAbs and plasma from 88 convalescent patients to emerging SARS-CoV-2 variants. Isolation of neutralizing mAbs from two convalescent patients 93 To identify potent neutralizing mAbs against SARS-CoV-2, we selected two patients A 94 and B who had recovered from severe COVID-19 (Table S1 ). These patients were 95 infected in March, 2020 during the first wave of SARS-CoV-2 prevalence in Japan. 96 Plasma samples from these patients had high binding activity to the SARS-CoV-2 97 Wuhan-Hu-1 S protein ( Figure 1A and Figure S1A ). Significant binding of plasma 98 samples to S was observed even at a 1:1,000,000 dilution, although the level of binding Figure 2D ), indicating that these mAbs were typical RBD-targeting neutralizing 127 antibodies observed in patients with COVID-19 (Barnes et al., 2020; Brouwer et al., 128 2020; Cao et al., 2020; Gaebler et al., 2021; Kim et al., 2021; Kreye et al., 2020; Wu et 129 al., 2020b) . Similar to the mAbs previously reported, these mAbs had a low somatic 130 hypermutation rate ranging from 1.03 % to 3.09 % in the VH gene and from 1.06 % to 131 2.44 % in the VK gene ( Figure 2D ). One non-RBD-targeting antibody, 6-74, bound to 132 the NTD of SARS-CoV-2 S protein, and had an extremely long CDRH3 ( Figure 2D ).

Neutralization activity of 6-74 was low compared with the RBD-targeting mAbs ( Figure   134 2A and C), but it had a strong inhibitory activity against SARS-CoV-2 S-mediated cell 135 fusion ( Figure 2B and C). All the neutralizing mAbs specifically neutralized 136 SARS-CoV-2 pseudovirus, but did not cross-neutralize SARS-CoV or MERS-CoV 137 pseudovirus in 293FT/ACE2/TMPRSS2 cells ( Figure 2C ). No neutralizing activity of 138 mAbs against MERS-CoV was also confirmed by infection of pseudovirus to Caco-2 139 cells, which express receptor for MERS-CoV, DPP4 (data not shown).

The neutralization potency of mAbs was proportional to their binding activity to the S 141 protein on the cell surface, although the NTD-targeting mAb, 6-74, bound to the S 142 protein with a greater affinity than the RBD-targeting mAbs with low neutralizing 143 activity ( Figure S1C ). The binding activity of 6-74 was equivalent to 10-121, which had 144 J o u r n a l P r e -p r o o f a 100-fold greater neutralizing activity against SARS-CoV-2 in 145 293FT/ACE2/TMPRSS2 compared with 6-74 ( Figure 2C and Figure S1C ). The 146 neutralizing activity of RBD-targeting mAbs was also consistent with the results of 147 surface plasmon resonance (SPR) analysis ( Figure S1D ). The most potent neutralizing 148 mAb, 9-105, bound to RBD with a dissociation constant (K D ) of 2.03x10 -12 M ( Figure   149 2D and Figure S1D ). 3.2-fold compared with that against the prototypic virus, respectively.

All the variants tested showed resistance to 6-74, suggesting that variants can easily 172 escape from this mAb targeting the NTD, perhaps due to mutations in the NTD ( Figure   173 3A). The efficacy of the RBD-targeting mAbs was decreased against P. 1 and B.1.351, 174 suggesting that the K417N/T, E484K and N501Y mutations in the RBD region are 175 critical for the resistance of these variants ( Figure 3A ). Analysis of single mutants 176 revealed that K417N and K417T were critical for escape from 3-5 and slightly 177 decreased potency of 8-92 ( Figure 3C lower panels). E484K and N501Y single 178 mutation did not conferred resistance to these RBD-targeting mAbs. However, (Figure 2A and C, and Figure 4B and C).

The neutralization activity of potent mAbs, 10-121 and 9-105, was also examined 

Variants were reported to be resistant to most NTD-targeting mAbs including 6-74 239 examined in this study (Graham et al., 2021; McCallum et al., 2021; Wang et al., 2021) . The RBD-targeting mAbs tested in this study are typical VH3-53 antibodies, which 

• This paper does not report original code.

• Any additional information required to reanalyze the data reported in this paper is 384 available from the lead contact upon request. The neutralization activity of antibodies was determined using HIV-1-based 495 pseudovirus with SARS-CoV-2 S, as previously described (Ozono et al., 2020 (Ozono et al., , 2021 In J o u r n a l P r e -p r o o f (A) Induction of antibodies against SARS-CoV-2 in two convalescent patients. Binding activity of plasma samples to the S protein was analyzed by flow cytometry. Binding of IgG at serially-diluted plasma samples is shown by mean fluorescence intensity (MFI). (B) Neutralization of SARS-CoV-2, SARS-CoV and MERS-CoV by plasma samples from patient A and B were analyzed using pseudoviruses. Plasma sample from healthy donor, which cross-neutralizes SARS-CoV and MERS-CoV, was used as a positive control (green triangle). Plasma sample from healthy donor, which does not neutralize SARS-CoV-2, SARS-CoV and MERS-CoV pseudoviruses, was used as a negative control (orange cross). Data are represented as means ± SD (n=3). (C) Binding activity of mAbs to the S protein was analyzed by flow cytometry. Binding of IgG to cells expressing SARS-CoV-2 S at 0.02 µg/ml of mAbs is shown by histogram (uppaer panel) . Binding of IgG at serially-diluted mAbs is shown by MFI (lower panel). Anti-HIV-1 V3 mAb 1C10 was used as a control. (D) Dissociation constant of mAbs against RBD was measured by SPR. KD values were determined by equilibrium analyses using nonlinear curve fitting of the Langmuir binding isotherm. A serially-diluted RBD (2-2500 nM) was injected over immobilized mAbs.

Log dilution . Two binding modes of VH3-53 antibodies were previously reported (Wu et al., 2020b) . Homology models were constructed based on COVA2-04 and COVA2-39, which are representative mAbs with different binding modes. Total energy of 9-105 homology model was low (-1213 Rosetta energy units [REU] ) when based on COVA2-04 compared with that based on COVA2-39 (-1129 REU). The original total energy was -1285 REU in COVA2-04 and -1256 REU in COVA2-39, respectively. Then, the 9-105 model based on the COVA2-04 with the lower total energy is shown. A schema of the model is drawn by Pymol. Magenta, light blue and gray ribbon represent heavy chain, light chain and RBD, respectively. An interface between 9-105 and RBD highlighted in green. (B) Interactions at the mutated residues in B.1.351 and P.1 variants are shown between RBD (gray) and 9-105 heavy chain (magenta) and light chain (light blue). (C) Alignment of CDRH3 amino acid sequences of 9-105, COVA2-04 and COVA2-39. COVA2-04 and COVA2-39 are representative VH3-53 antibodies with different binding modes (Brouwer et al., 2020) . Binding modes of IGHV3-53 antibodies depend on CDRH3 length, and the CDRH3 of 9-105 is close to that of COVA2-04. 

SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and 606 healthy individuals

A Therapeutic 609

Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a 610 COVID-19 Hamster Model

Trisaccharide containing 613 α2,3-linked sialic acid is a receptor for mumps virus

Early 616 transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the

Effect of Convalescent Plasma Therapy on Time to Clinical 620

Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized 621 Clinical Trial

Potent neutralizing antibodies against multiple epitopes 624 on SARS-CoV-2 spike

Convalescent 627 plasma treatment of severe COVID-19: a propensity score-matched control study

Detected in Traveler Returning from Brazil to Italy

N-terminal domain antigenic 634 mapping reveals a site of vulnerability for SARS-CoV-2

Neutralization of SARS-CoV-2 lineage

B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science

Super-rapid quantitation of the production of HIV-1 harboring a luminescent peptide

SARS-CoV-2 D614G spike mutation increases 644 entry efficiency with enhanced ACE2-binding affinity

A dynamic nomenclature proposal for SARS-CoV-2 647 lineages to assist genomic epidemiology

Complementary and synergistic activities of anti-V3, CD4bs 650 and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 651 strains

5-amino levulinic acid inhibits SARS-CoV-2 654 infection

Antibody 657 potency, effector function, and combinations in protection and therapy for 658 SARS-CoV-2 infection in vivo

SARS-CoV-2 variant B.1.1.7 is susceptible 661 to neutralizing antibodies elicited by ancestral spike vaccines

PyIR: a scalable wrapper for 665 processing billions of immunoglobulin and T cell receptor sequences using IgBLAST

Prospective mapping of viral mutations that 669 escape antibodies used to treat COVID-19

Reduced 672 neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Neutralization of viruses with European, South African, 676 and United States SARS-CoV-2 variant spike proteins by convalescent sera and 677

BNT162b2 mRNA vaccine-elicited antibodies

Detection of a SARS-CoV-2 680 variant of concern in South Africa

Efficient generation of monoclonal antibodies from single human B cells by 683 single cell RT-PCR and expression vector cloning

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and 687 B.1.1.7. Nature

REGN-COV2, a Neutralizing Antibody 690

Outpatients with Covid-19

Mutation Increases SARS CoV-2 Susceptibility to Neutralization

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor 698 plasma

A new coronavirus associated with human 701 respiratory disease in China

mRNA-1273 vaccine 704 induces neutralizing antibodies against spike mutants from global SARS-CoV-2 705 variants

An Alternative Binding Mode of 708 IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion 713

Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner

Structural and 717 Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

A pneumonia outbreak associated with a new 721 coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China